지씨셀, NK·T세포 악성종양 CAR-T ‘GCC2005’ 1상 IND 신청

GC Cell's IND submission for GCC2005 marks a strategic expansion of its CAR-T pipeline into the NK-T cell lymphoma segment, transitioning from preclinical development to clinical validation. The addition of single-dose and multi-dose cohorts enables comprehensive safety and efficacy data collection to support Phase 2 advancement, establishing critical evidence for potential commercialization in this underexplored hematologic malignancy indication. While Phase 1 success is not guaranteed, this clinical milestone demonstrates GC Cell's commitment to broadening its cell therapy portfolio beyond initial programs.